Skip to content
value.today

Bonum Therapeutics, Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2021
Total raised
$73 M
3 rounds on record
Latest round
$27 M
Apr 2026
First round on record
Dec 2021
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Bonum Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$27 MNo. 3$10 to $50 million

Bonum Therapeutics, Inc.: Raise no. 3, Apr 2026

Investors in this round

8 investors had bought by the notice of Apr 17, 2026: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $32 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Diane Hollenbaugh · Executive Officer
  • John Mulligan · Executive Officer, Director, Promoter
  • Neela Patel · Executive Officer
  • Gaurav Aggarwal · Director
  • John McKearn · Director
  • Karl Handelsman · Director
  • Mitchell Mutz · Director
  • Monique Schiersing · Director
  • Nicholas Walrod · Director
  • Samuel Bjork · Director
  • Samuel Blackman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Mulligan, Chief Executive Officer. Newest notice filed Apr 17, 2026. Read the notice at the SEC.

equitySEC
Nov 2022$45 MNo. 2$10 to $50 million

Bonum Therapeutics, Inc.: Raise no. 2, Nov 2022

Investors in this round

10 investors had bought by the notice of Nov 29, 2022: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $93 M offered; $48 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Diane Hollenbaugh · Executive Officer
  • John Mulligan · Executive Officer, Director, Promoter
  • Neela Patel · Executive Officer
  • John McKearn · Director
  • Karl Handelsman · Director
  • Mitchell Mutz · Director
  • Monique Schiersing · Director
  • Nicholas Walrod · Director
  • Samuel Bjork · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Mulligan, Chief Executive Officer. Newest notice filed Nov 29, 2022. Read the notice at the SEC.

equitySEC
Dec 2021$1 MNo. 1Under $2 million

Bonum Therapeutics, Inc.: Raise no. 1, Dec 2021

Investors in this round

5 investors had bought by the notice of Dec 22, 2021: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Diane Hollenbaugh · Executive Officer
  • John Mulligan · Executive Officer, Director, Promoter
  • Neela Patel · Executive Officer
  • John McKearn · Director
  • Karl Handelsman · Director
  • Monique Schiersing · Director
  • Nicholas Walrod · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Mulligan, Chief Executive Officer. Newest notice filed Dec 22, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Bonum Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2026).

    SEC Form D · Apr 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Bonum Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Bonum Therapeutics, Inc.
NameRoleNamed in
Diane HollenbaughExecutive officerApr 2026
John MulliganExecutive officerApr 2026
Neela PatelExecutive officerApr 2026
Gaurav AggarwalDirectorApr 2026
John McKearnDirectorApr 2026
John MulliganDirectorApr 2026
Karl HandelsmanDirectorApr 2026
Mitchell MutzDirectorApr 2026
Monique SchiersingDirectorApr 2026
Nicholas WalrodDirectorApr 2026
Samuel BjorkDirectorApr 2026
Samuel BlackmanDirectorApr 2026
John MulliganPromoterApr 2026